There are more than 100 types of known cancers. In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.
In this current environment, the successful players of the future will be those that can anticipate evolution and design the most relevant clinical trials (Regen are certainly doing that). In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.
With a heightened awareness created by many renowned cancer specialists in the world, governments are being forced to take a much closer look at the manipulation perpetuated by pharmaceutical companies in their efforts to continue to profit ungodly amounts at the risk of patients. Many are accused of profiteering by way of the astronomical prices for cancer treatments almost all cancer patients are desperate for. Often times these treatments offer a Band-Aid solution, requiring new application and never at a discounted price.
Further, increased awareness to the alternative treatments of cancer is moving through the world at an incredible rate. Gone are the days when the only option for any hope to battling cancer was by way of toxic treatments.
As I have said, what BMSN holds, is the wave of the future. A wave that pharma are going to have to pay very close attention to in order to maintain their positions as the big fish they are.
RNA Interference (Min Science) specifically inhibits the enzyme IDO. Tumors can escape the immune system by specifically activating the IDO enzyme. Dr. Min along with his team, clearly demonstrated that by blocking function of IDO, tumors enter remission. But with the recent Benitec licensing, they are going one step further in combating cancer by not only effectively inhibiting the IDO's but also stimulating the immune system to kill the cancer cells.
So, not only are they targeting the cancer cells with environmental friendly fire they are working to teach the body to eliminate the forces that infiltrate and create the environment conducive for cancer cell proliferation.
A double whammy to one of the ugliest plagues life has seen. And a double whammy that you can bet your money that in very short order, BP will be utilizing. And they ain’t getting it for free!
I just increased my GTC to 10.00. :)
LONG BMSN!
News 
Market Data 
Discover 
